Hotstocked Newsletters

Promoted Companies

PROMOTION HISTORY
SORT BY:

ArQule Inc. (ARQL)

Total paid for Promotions this month: $0
E-mails this Month: 4
Estimated Volume Generated: $0
Research Report on ARQL: Click to see
* The information presented is based on information for Jan , 2014
Biotech Alert: Positive Clinical Trials Update Could Attract Radar Signals (Mailing list information, including unsubscription instructions, is located at the end of this message.)   ArQule Inc. (ARQL)   Keep a close eye on ARQL. The company provided positive clinical updates on the ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma (liver cancer), and on the completed amended Phase 3 ATTENTION trial in non-squamous ...read more
Promoter: Crweselect.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ARQL Unknown compensation UNKNOWN
Max Profit: 4.66 % Gain at close: -9.68 %
Biotech Alert: Positive Clinical Trials Update Could Attract Radar Signals (Mailing list information, including unsubscription instructions, is located at the end of this message.)   ArQule Inc. (ARQL)   Keep a close eye on ARQL. The company provided positive clinical updates on the ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma (liver cancer), and on the completed amended Phase 3 ATTENTION trial in non-squamous ...read more
Promoter: pennyomega.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ARQL Unknown compensation UNKNOWN
Max Profit: 4.66 % Gain at close: -9.68 %
Biotech Alert: Positive Clinical Trials Update Could Attract Radar Signals (Mailing list information, including unsubscription instructions, is located at the end of this message.)   ArQule Inc. (ARQL)   Keep a close eye on ARQL. The company provided positive clinical updates on the ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma (liver cancer), and on the completed amended Phase 3 ATTENTION trial in non-squamous ...read more
Promoter: stockbling.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ARQL Unknown compensation UNKNOWN
Max Profit: 4.66 % Gain at close: -9.68 %
Biotech Alert: Positive Clinical Trials Update Could Attract Radar Signals (Mailing list information, including unsubscription instructions, is located at the end of this message.)   ArQule Inc. (ARQL)   Keep a close eye on ARQL. The company provided positive clinical updates on the ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma (liver cancer), and on the completed amended Phase 3 ATTENTION trial in non-squamous ...read more
Promoter: penny to buck Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ARQL Unknown compensation UNKNOWN
Max Profit: 4.66 % Gain at close: -9.68 %
Video not found or You must install the Flash Plugin for your Browser in order to view this movie